ClinicalTrials.gg
Enrolling by invitationNCT03388476EARLIERUpdated May 19, 2022

Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension

An observational study in Hypertension, Pulmonary, Hypertension;Pulmonary;Primary and Chronic Thromboembolic Pulmonary Hypertension, sponsored by University of Giessen. Enrolling by invitation at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-19.

Sponsored by University of Giessen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hypertension, Pulmonary by University of Giessen — 5 open to participants now, 5 under way, none of them phase 3. Hypertension, Pulmonary · University of Giessen.

Planned enrollment
5th of 11
500 · median 500
Started
2018
the only one that year
Observational
11 of 13
5 open now
Registered
6th of 13
by date

Among the 13 studies in Hypertension, Pulmonary by University of Giessen, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2018, is one of 11 observational ones, and was the 6th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

5 of the 13 studies in Hypertension, Pulmonary by University of Giessen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hypertension, Pulmonary by University of Giessen, or all of them as a file.
02

Study summary

Measurement of the endtidal carbon dioxide by capnography to exclude or to ensure the diagnosis pulmonary hypertension. The aim of the study is to obtain an endtidal carbon dioxide cut-off value for the diagnostic algorithm for pulmonary hypertension as an easily measurable and cheap diagnostic tool in patients with suspicion of pulmonary hypertension.

Read the detailed description

The disease pulmonary hypertension is due to a remodeling of the lung vessels which results in a change of the exhaled air. This change is measurable with a so called capnograph. The investigators want to measure the breath from patients with and without pulmonary hypertension to detect a cut-off value for the diagnosis pulmonary hypertension.

Patients which have the probably diagnosis pulmonary hypertension and are older than 18 years are investigated. This patients will get an right heart catheterization and a measurement from their exhaled air.

03

Conditions studied

  • Hypertension, Pulmonary
  • Hypertension;Pulmonary;Primary
  • Chronic Thromboembolic Pulmonary Hypertension
  • Vascular Diseases
  • Lung Diseases

Keywords

  • pulmonary hypertension
  • endtidal co2
  • endtidal carbon dioxide
  • pulmonary arterial hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients of a tertiary referral center retro- and prospective part of the study.

Afterwards in a next prospective study part patients in ambulant setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age > 18 years, suspicion of pulmonary hypertension, planned or accomplished right heart catheterization

Exclusion criteria

Exclusion Criteria:

none

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Suspicion of pulmonary hypertension

    At Patients with suspicion of pulmonary hypertension, which get a right heart catheterization, in the context of the study the exhaled air, precious the endtidal carbon dioxide (CO2), before or after the right heart catheterization will be measured through capnography.

    Diagnostic Test: Capnography

Interventions

  • Diagnostic testCapnography

    Measuring of the exhaled air, especially endtidal co2, through capnography.

06

What researchers measure

Primary outcomes

  1. Measurement PetCO2

    Measurement PetCO2 by capnography at rest after or before a right heart catheterization, comparison of the parameter between patients with and without

    Time frame: At baseline

Secondary outcomes

  1. Establishing a cut-off

    Establishing a cut-off for the non-invasive diagnosing of pulmonary hypertension, which differs between patients with and without pulmonary hypertension and save patients without the disease before a dispensable invasive right heart catheterization

    Time frame: At baseline

07

Study locations

1 site
  • University Clinic Giessen and Marburg
    Giessen, Hessen 35392, Germany
08

References and documents

Publications

  • Hemnes AR, Pugh ME, Newman AL, Robbins IM, Tolle J, Austin ED, Newman JH. End tidal CO(2) tension: pulmonary arterial hypertension vs pulmonary venous hypertension and response to treatment. Chest. 2011 Nov;140(5):1267-1273. doi: 10.1378/chest.11-0155. Epub 2011 May 26. PubMed 21622547 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Jan 2030, 139 months after the start.

Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 139 months is above that.

Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2017
First posted
Jan 3, 2018
StartActual
May 2, 2018
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2035
Last update
May 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03388476
Lead sponsor
University of Giessen
Responsible party
Sophie Herbst (Study Chair: Ghofrani H. Ardeschir, Prof. Dr. University of Giessen, University of Giessen) — Principal investigator
First posted
Jan 3, 2018
Start date
May 2, 2018
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2035 (estimated)
Last update
May 19, 2022

Study contacts

Henning Gall, MD, PhD
principal investigator · University Clinic Giessen and Marburg - Campus Giessen
Werner Seeger, Prof.
study director · University Clinic Giessen and Marburg
Ardeschir Ghofrani, Prof.
study director · University Clinic Giessen and Marburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion